Ashley Wagner, PA
Medical · Crestview, FLNPI 1205078706
Payments from drug & device makers
Across 324 payments — averaging $17.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Johnson & Johnson$775
- Regeneron Healthcare Solutions, Inc.$536
- Sun Pharmaceutical Industries Inc.$436
- Novartis$436
- Sanofi$415
- plus $1K from 16 others
What the payments were for
- Food & beverage$5,42295%
- Education$2685%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 110 | $1,741 |
| Johnson & Johnson | 45 | $775 |
| Regeneron Healthcare Solutions, Inc. | 26 | $536 |
| Sun Pharmaceutical Industries Inc. | 17 | $436 |
| Novartis | 28 | $436 |
| Sanofi | 18 | $415 |
| E.r. Squibb & Sons, L.L.C. | 19 | $281 |
| Amgen | 10 | $201 |
| Pfizer | 9 | $142 |
| LEO Pharma Inc. | 9 | $126 |
| Galderma Laboratories, L.p. | 8 | $121 |
| Incyte Corporation | 6 | $116 |
| Lilly USA, LLC | 4 | $94 |
| Biofrontera Inc. | 3 | $53 |
| Nabriva Therapeutics, PLC | 3 | $51 |
| Almirall LLC | 2 | $42 |
| Arcutis Biotherapeutics, Inc. | 2 | $35 |
| Hill Dermaceuticals, Inc. | 1 | $26 |
| Stemline Therapeutics Inc. | 1 | $25 |
| UCB, Inc. | 1 | $17 |
| Organogenesis Inc. | 1 | $16 |
| Organon | 1 | $5 |
How this compares
$5,691 in reported general payments places this provider in the 85th percentile of 2,031 medical providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 12 | $244,971 |
| Dupixent PenDupilumab | 31 | $113,322 |
| Clobetasol Propionate | 58 | $3,548 |
| Fluorouracil | 43 | $3,068 |
| Doxycycline Hyclate | 15 | $551 |
| Ketoconazole | 23 | $263 |
| Triamcinolone Acetonide | 16 | $158 |
| Mupirocin | 18 | $140 |
Paid to pharmacies, not to this prescriber.
Other medical in Crestview
- Gary RubinRockledge$2.1M
- Shanna MirantiNaples$415K
- Krystie LennoxBoca Raton$245K
- Jihan RamadanWellington$238K
- Ilanit SamuelsMiami$211K
- Erin DouceyWinter Haven$202K
- Kathleen TrummerWellington$166K
- Sandra SnyderTampa$156K
- Francine PhillipsLand O Lakes$145K
- Chelsie FerrellDeland$132K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.